OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.

OPKO Health (NASDAQ:OPK) Stock Price Crosses Above 50 Day Moving Average - Here

OPKO Health stock is backed by stronger Q2 2026 figures, with revenue up year on year and losses sha

On August 13, OPKO Health (NASDAQ:OPK) expanded its financing relationship with HealthCare Royalty, a business of KKR, issuing an additional $125 million in senior secured notes secured by the royalty stream tied to mazdutide, the GLP-1 drug OPKO licensed to Eli Lilly and now collects royalties on in China. The notes mature in 2044, matching […]

OPKO Health (NASDAQ:OPK) outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development. Speaking

OPKO Health (NASDAQ:OPK) outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development. Speaking

Bank of New York Mellon Corp purchased a new position in OPKO Health, Inc. (NASDAQ:OPK - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 1,329,974 shares of the biotechnology company

OPKO Health (NASDAQ:OPK) Hits New 12-Month High - Here

OPKO Health (NASDAQ:OPK) Shares Up 8.2% - Should You Buy?

BlackRock Inc. bought a new stake in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 36,978,893 shares of the biotechnology company